Welcome to our dedicated page for Immuron news (Ticker: IMRN), a resource for investors and traders seeking the latest updates and insights on Immuron stock.
Immuron Limited develops and commercializes orally delivered targeted polyclonal antibodies for gastrointestinal infectious diseases. The Australian biopharmaceutical company uses a hyper-immune bovine colostrum platform and markets Travelan®, an over-the-counter product for travelers’ diarrhea and digestive tract protection, in Australia, the United States and Canada.
Recurring news covers Travelan sales by region, the Australian launch of ProIBS®, research funding and collaborations for enteric pathogens, and updates on clinical programs such as IMM-124E and IMM-529. Company announcements also discuss operating results, strategic updates, distribution expansion and investor conference presentations tied to its ASX and Nasdaq listings.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Immuron Limited (ASX: IMC; NASDAQ: IMRN) has released its Q3 FY23 Investor Presentation, highlighting significant sales growth. For the two weeks ending April 14, 2023, worldwide sales reached A$320,000, representing 37% of the entire Q3 FY23 total of A$875,000. Year-to-date sales for FY23 until April 14 amounted to A$1,779,000, marking a remarkable 233% increase compared to A$534,000 for the same period in FY22. The company is focusing on its oral immunotherapeutic products for gut-mediated diseases. Investors are invited to participate in a webinar hosted by CEO Steven Lydeamore for further insights.
Immuron Limited (ASX: IMC; NASDAQ: IMRN), a biopharmaceutical company based in Australia, announced a business update for the quarter ending 31 March 2023. The update will be presented during a live webcast hosted by CEO Steven Lydeamore on 19 April 2023 at 11:00 AM (AEST). The company is known for its orally administered immunotherapeutic products, particularly Travelan®, which is used to prevent travelers' diarrhea. Travelan® is available in Australia and Canada as a therapeutic product and a licensed natural health product, respectively, and in the U.S. as a dietary supplement. The company is focused on developing targeted polyclonal antibodies for treating inflammatory and infectious diseases.
Immuron Limited (ASX: IMC; NASDAQ: IMRN) reported robust sales results for Q3 FY23, highlighting a significant turnaround in demand for its gastrointestinal products, Travelan® and Protectyn®.
Sales soared to A$1.46 million year-to-date, reflecting a 239% increase from A$430k in the same period last year. In Australia, Q3 FY23 sales reached A$577k, representing 201% of first-half sales. North American sales mirrored this trend, with Q3 reaching A$298k, equating to 100% of first-half sales.
This growth is attributed to a rebound in overseas travel and increasing sales through clinics and distributors, emphasizing the company’s strategy to restock and build inventory. Immuron remains committed to expanding its product portfolio and driving sales growth.
Immuron Limited (ASX: IMC; NASDAQ: IMRN), a biopharmaceutical company based in Australia, invites investors to a live webcast hosted by CEO Steven Lydeamore on February 28, 2023, at 11:00 AM AEDT. Immuron specializes in developing oral immunotherapeutic products for gut-mediated diseases, with its flagship product, Travelan®, approved in Australia and Canada to reduce the risk of Travelers' Diarrhea. In the U.S., it is marketed as a dietary supplement. This event aims to provide insights into the company's product offerings and future plans.